Forge Biologics, a cell and gene therapy-focused CDMO, used the week to underscore its positioning in advanced manufacturing, regulatory navigation, and talent development. The company highlighted thought leadership around gene therapy regulation, European market support, and the transition from research to scalable production.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Forge reported active engagement with regulators through its Scientific and Medical Advisory Board, emphasizing how CDMOs can inform evolving gene therapy frameworks. Management also cited broader industry commentary from its CEO on manufacturing bottlenecks, framing Forge as a partner for complex biologics at scale.
In Europe, Forge showcased capabilities supporting adeno-associated virus developers from early research-grade material through clinical trial applications under U.K. and EU rules. This emphasis on regulatory guidance and manufacturing services in a growing regional market may help deepen relationships with both emerging and established sponsors.
The company also spotlighted participation in the Gene Therapy Institute’s symposium in Columbus, where it presented work on scaling therapies from research to manufacturing. Forge positioned this ecosystem engagement as a way to build ties with academic and early-stage innovators that could mature into future client relationships.
On the human capital front, Forge highlighted the recognition of employee Danielle Sexton as a COSI STEAM Star and her mentoring of future scientists, underscoring its focus on diversity and talent retention. The company additionally hosted local STEM students for a hands-on gene therapy facility visit, reinforcing its long-term workforce pipeline efforts.
Forge reported achieving My Green Lab Certification across all laboratories and cGMP suites, describing the sustainability milestone as integral to operational excellence and ESG priorities. Overall, the week’s updates present a company investing in regulatory expertise, ecosystem presence, workforce development, and sustainability that could support future commercial growth and client stickiness.